RGRayna J. Gonzales

Rayna J. Gonzales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rayna J. Gonzales has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Trevor Scott Wendt

    Applied Neurovascular Research, Neurosurgery, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden

    6 shared publications
  • Qiang Liu

    Department of Neurology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center

    3 shared publications
  • Lakshmi Madhavpeddi

    Department of Basic Medical Sciences, University of Arizona College of Medicine - Phoenix , Phoenix, Arizona

    2 shared publications
  • Puneet Raman

    Department of Basic Medical Sciences, University of Arizona College of Medicine - Phoenix , Phoenix, Arizona

    2 shared publications
  • Robert J. Handa

    2 shared publications
  • Trevor S. Wendt

    Department of Basic Medical Sciences, University of Arizona, Phoenix, AZ, United States

    2 shared publications

Latest Publications

  • Open Access

    Towards Quantitative In Vitro Modelling of Focused Ultrasound-mediated Blood-Brain Barrier Opening using an Ultrasound-transparent Organ-on-Chip Device

    by Nabhan M Fakrudin, Nathan Han, Laith Kabbani, Brandon Lan, Suzan Aldekr, Baiju Thomas, Matthew W Barrett, Rayna J Gonzales, Frederic Zenhausern, Jian Gu

    Gas-bubble-enhanced focused ultrasound (FUS GB ) is advancing clinically across a myriad of applications, including targeted drug delivery through transient blood-brain barrier opening (BBBO). Its broader translation requires a better understanding of the bioeffects that enable reproducible enhancement of barrier permeability while avoiding vascular injury, underscoring the need to clarify the relationship between acoustic exposure, bubble activity, and the biological response central to treatment optimization. These interactions are difficult to isolate in vivo, and acoustic reflections, geometry, and field distortion in conventional cultureware hinder quantitative in vitro studies. Herein, we present a theoretically and experimentally characterized ultrasound-transparent organ-on-chip device with >99.9% US transparency that enables quantitative in vitro modeling of the FUS GB procedure and study of BBBO. Furthermore, submicron bubbles (sMB, ~800nm) were fabricated and characterized. Acoustic dose-dependent subharmonic and broadband cavitation dose curves (SCD and BCD), as well as temporal responses, were studied. A 3-day accelerated Caco—2 surrogate barrier with a high TEER (~1200×cm2) was used to demonstrate US dose-dependent targeted barrier opening, visualized using an in vitro Evans Blue assay. Together, this study and its findings establish a foundation for quantitative in vitro modeling of FUS BBBO, as well as other US interactions in microphysiological systems, supporting systematic evaluation of procedural regimens, large-parameter-space optimization, acoustic safety window, and exposure conditions for brain drug delivery, and additionally enabling mechanistic insight into FUS GB BBBO.

  • Open Access

    Differential S1PR Expression and Altered Barrier, and Inflammatory Marker Levels in Human Brain Endothelial Cells Following Acute Ischemia-Reperfusion Like Injury

    by Trevor S. Wendt, Nafis B. Eghrari, Matthew C. Lyons, Yasmin Beer, Rayna J. Gonzales

    There are five known sphingosine-1-phosphate receptor (S1PR) types, and each type is coupled to diverse heterotrimeric G-protein subunits. S1PR type 1 (S1PR1) is highly expressed in the endothelium and receptor signaling pathways beneficially impact barrier function, thus there is a growing interest in the potential therapeutic role of S1PR1 during acute stroke injury. However, assessment of cerebrovascular S1PR1 and other S1PR expression profiles following acute ischemia-reperfusion injury have not yet been investigated. Therefore, we assessed the expression profile of human brain microvascular endothelial (HBMEC) S1PR1-5 following hypoxia plus glucose deprivation (HGD) exposure and HGD with reperfusion (HGD/R). We also investigated endothelial tight junction barrier and inflammatory mediator expression, indicative of an activated endothelial phenotype post HGD or HGD/R. Additionally, we investigated the effect of IL-1β, a downstream HGD induced inflammatory mediator, on endothelial mRNA expression of markers of function, barrier integrity, and inflammation and determined whether selective S1PR1 agonism altered mRNA expression of these genes. In terms of S1PR expression, a differential mRNA expression profile was observed revealing prominent basal endothelial expression of S1PR1-3. Following HGD, S1PR1 mRNA and protein expression increased with no observed changes in S1PR2 or S1PR3 protein levels. HGD/R increased endothelial inflammatory mediator and occludin mRNA expression with a temporal-dependent decrease in endothelial S1PR1 and claudin-5. Interestingly, we observed a positive and negative correlation between S1PR1 and S1PR2/3 with claudin-5, respectively. Selective S1PR1 agonism attenuated IL-1β induced MMP-9 mRNA and activity. In conclusion, HGD/R acutely increases endothelial cell expression of S1PR1 which presents a potential therapeutic target within the cerebrovasculature following ischemia-reperfusion injury. Additionally, HGD/R may potentially induce a phenotypic transformation within HBMECs, in which occludin expression predominates over claudin-5. NEW & NOTEWORTHY: Abstract Figure: Graphical

  • Open Access

    OxLDL/LOX-1 mediated sex, age, stiffness, and endothelial dependent alterations in mouse thoracic aortic vascular reactivity

    by Trevor S. Wendt, Saema Ansar, Rayna J. Gonzales

    Elevated plasma levels of oxidized low-density lipoprotein (oxLDL) are a risk factor and key component that accelerates and worsens cardiovascular disease fueling inflammation, plaque buildup and vascular damage. OxLDL can elicit its detrimental action via lectin-like oxLDL receptor 1 (LOX-1). In this study, we determined whether oxLDL, via LOX-1, alters aortic vascular reactivity and determined if sex and age differences exist. Thoracic aortic endothelium-intact or -denuded ring segments were isolated from 7 to 12 months old intact C57BL/6J female and male mice and pre-incubated with oxLDL ex vivo (50ug/dL; 2 h). Using wire myography, cumulative concentration-response curves to phenylephrine (PE) were generated to determine contractile responses. From these curves, the EC50 was determined and used to contract rings to assess acetylcholine (ACh) dependent relaxation. Calculated aortic stiffness and remodeling were also assessed. BI-0115 (10 μM; selective LOX-1 inhibitor) was used to determine LOX-1 dependence. We observed differential sex, age, endothelial cell, and LOX-1 dependent alterations to the efficacy of PE-induced contractile responses and ACh-mediated vasorelaxation in thoracic aortic rings following oxLDL exposure. Additionally, we observed a distinct sex and age effect on thoracic aortic stiffness following exposure to oxLDL. There was also a sex effect on calculated vessel diameter, as well as an age effect on oxLDL-mediated aortic remodeling that was LOX-1 dependent. Thus, LOX-1 inhibition and the resulting attenuation of oxLDL/endothelial-mediated alterations in aortic function suggests that there are differential sex differences in the role of oxLDL/LOX-1 in the thoracic aorta of middle-aged male and female mice. NEW and NOTEWORTHY. We investigated the effects of oxLDL via the LOX-1 receptor on murine thoracic aortic vasoreactivity, stiffness, and remodeling across age and sex. Acute exposure to oxLDL led to altered vasoreactivity, endothelial dysfunction, and changes in aortic stiffness and remodeling. These effects were in-part age, sex, endothelial, and LOX-1 dependent. This study reveals potential complex interactions in oxLDL/LOX-1-mediated vascular responses that could serve as potential therapeutic intervention for vascular diseases such as atherosclerosis and stroke.


  • Top Cited Papers

    LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke

    by Kajsa Arkelius, Trevor S. Wendt, Henrik Andersson, Anaële Arnou, Michael Gottschalk, Rayna J. Gonzales, Saema Ansar

    BACKGROUND: Acute ischemic stroke triggers endothelial activation that disrupts vascular integrity and increases hemorrhagic transformation leading to worsened stroke outcomes. rt-PA (recombinant tissue-type plasminogen activator) is an effective treatment; however, its use is limited due to a restricted time window and hemorrhagic transformation risk, which in part may involve activation of MMPs (matrix metalloproteinases) mediated through LOX-1 (lectin-like oxLDL [oxidized low-density lipoprotein] receptor 1). This study’s overall aim was to evaluate the therapeutic potential of novel MMP-9 (matrix metalloproteinase 9) ± LOX-1 inhibitors in combination with rt-PA to improve stroke outcomes. METHODS: A rat thromboembolic stroke model was utilized to investigate the impact of rt-PA delivered 4 hours poststroke onset as well as selective MMP-9 (JNJ0966) ±LOX-1 (BI-0115) inhibitors given before rt-PA administration. Infarct size, perfusion, and hemorrhagic transformation were evaluated by 9.4-T magnetic resonance imaging, vascular and parenchymal MMP-9 activity via zymography, and neurological function was assessed using sensorimotor function testing. Human brain microvascular endothelial cells were exposed to hypoxia plus glucose deprivation/reperfusion (hypoxia plus glucose deprivation 3 hours/R 24 hours) and treated with ±tPA and ±MMP-9 ±LOX-1 inhibitors. Barrier function was assessed via transendothelial electrical resistance, MMP-9 activity was determined with zymography, and LOX-1 and barrier gene expression/levels were measured using qRT-PCR (quantitative reverse transcription PCR) and Western blot. RESULTS: Stroke and subsequent rt-PA treatment increased edema, hemorrhage, MMP-9 activity, LOX-1 expression, and worsened neurological outcomes. LOX-1 inhibition improved neurological function, reduced edema, and improved endothelial barrier integrity. Elevated MMP-9 activity correlated with increased edema, infarct volume, and decreased neurological function. MMP-9 inhibition reduced MMP-9 activity and LOX-1 expression. In human brain microvascular endothelial cells, LOX-1/MMP-9 inhibition differentially attenuated MMP-9 levels, inflammation, and activation following hypoxia plus glucose deprivation/R. CONCLUSIONS: Our findings indicate that LOX-1 inhibition and ± MMP-9 inhibition attenuate negative aspects of ischemic stroke with rt-PA therapy, thus resulting in improved neurological function. While no synergistic effect was observed with simultaneous LOX-1 and MMP-9 inhibition, a distinct interaction is evident.


  • Ozanimod differentially preserves human cerebrovascular endothelial barrier proteins and attenuates matrix metalloproteinase-9 activity following in vitro acute ischemic injury

    by Trevor S. Wendt, Rayna J. Gonzales

    We have identified a potential novel mechanism by which ozanimod, a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, attenuates hypoxia plus glucose deprivation (HGD)-induced matrix metalloproteinase-9 (MMP-9) activity and disruptions in integral human brain endothelial cell barrier proteins. Our results suggest that ischemic-like injury elicits increased MMP-9 activity and alterations of barrier integrity proteins in human brain microvascular endothelial cells (HBMECs) and that ozanimod via S1PR1 attenuates these HGD-induced responses, adding to its therapeutic potential in cerebrovascular protection during the acute phase of ischemic stroke.


  • Open Access

    OxLDL/LOX-1 Mediated Sex, Age, and Cell Dependent Alterations in Mouse Thoracic Aortic Vascular Reactivity

    by Trevor Scott Wendt, Rayna J. Gonzales

    Elevated oxidized low-density lipoprotein (oxLDL) is a risk factor and component that worsens cardiovascular disease states. OxLDL can elicit its detrimental action, via lectin-like oxLDL receptor 1 (LOX-1) and has been shown to disrupt vascular function. In this study, we determined whether oxLDL, via LOX-1, alters aortic vascular reactivity and determined if sex differences exist. Thoracic aortic endothelium-intact or -denuded ring segments were isolated from intact C57BL/6J female and male mice and incubated with oxLDL ex vivo (50ug/dL; 2h). Using wire myography, cumulative concentration-response curves to phenylephrine (PE) were generated to determine contractile responses. From these curves, the EC50 was determined and used to contract rings to assess acetylcholine (ACh) dependent relaxation. Calculated aortic stiffness and remodeling, as well as mRNA expression of vasoactive and pro-inflammatory mediators were assessed. BI-0115 (10 μ M; selective LOX-1 inhibitor) was used to determine LOX-1 dependence. We observed differential sex, age, endothelial cell, and LOX-1 dependent alterations to the efficacy of PE-induced contractile responses and ACh-mediated vasorelaxation in the thoracic aortic rings following oxLDL exposure. Additionally, we observed a distinct sex and age effect on thoracic aortic stiffness following exposure to oxLDL. There was also a sex effect on calculated vessel diameter, as well as an age effect on oxLDL-mediated inward remodeling that was LOX-1 dependent. Thus, LOX-1 inhibition and the resulting attenuation of oxLDL/endothelial-mediated alterations in aortic function suggests that there are differential sex differences in the role of oxLDL/LOX-1 in the thoracic aorta of male and female mice. NEW & NOTEWORTHY: We investigated the effects of oxidized low-density lipoprotein (oxLDL) via the LOX-1 receptor on murine thoracic aortic vasoreactivity, stiffness, and remodeling across age and sex. Acute exposure to oxLDL led to altered vasoreactivity, endothelial dysfunction, and changes in aortic stiffness and remodeling. These effects were in-part age, sex, endothelial, and LOX-1 dependent. This study reveals potential complex interactions in oxLDL/LOX-1-mediated vascular responses that could serve as potential therapeutic intervention for vascular diseases such as atherosclerosis.

  • Open Access

    Selective S1PR1 activation improves brain infarction, neurological outcome, and cerebrovascular endothelial health following experimental ischemic injury

    by Samuel X. Shi, Yu-Jing Li, Trevor S. Wendt, Kaibin Shi, Weina Jin, Qiang Liu, Rayna J. Gonzales

    Sphingosine-1-phosphate receptor 1 (S1PR1) is highly expressed in endothelial cells and receptor activation plays an important role in mediating endothelial function and health, thus showing promise as a pharmacologic target for acute ischemic stroke (AIS) treatment. Here, we examined the effect of a selective S1PR1 ligand, RP101075, on infarct volume and neurological outcome in adult male mice subjected to transient middle cerebral artery occlusion (tMCAO). Concomitantly, we examined S1PR1 expression profile in the ischemic mouse brain, as well as S1PR1 expression and impact of receptor activation on human brain microvascular endothelial cell (HBMEC) proliferation and survival following hypoxia plus glucose deprivation (HGD). We observed that RP101075 administration at onset of reperfusion reduced infarct volume and lessened neurological deficits in tMCAO mice and these responses were S1PR1 dependent. Additionally, we observed that tMCAO increased brain S1PR1 protein levels and flow cytometry revealed increases in S1PR1 levels are greatest in brain endothelial cells compared to other brain cell types (astrocyte, neuron, microglia). In cultured HBMECs, RP101075 increased cell proliferation and ozanimod, parent compound of RP1010175, increased live cell count during HGD; this response was S1PR1 dependent. In conclusion, S1PR1 activation improves neuroprotection/outcome post-stroke and preserves brain endothelial cell survival following ischemia-like injury.

  • Open Access

    Ozanimod Attenuates Human Cerebrovascular Endothelial Derived MMP-9 Activity and Preserves Barrier Properties Following In Vitro Acute Ischemic Injury

    by Trevor S. Wendt, Rayna J. Gonzales

    Endothelial integrity is critical in mitigating a vicious cascade of secondary injuries following acute ischemic stroke (AIS). Matrix metalloproteinase-9 (MMP-9), a contributor to endothelial integrity loss, is elevated during stroke and is associated with worsened stroke outcome. We investigated the FDA approved selective sphingosine-1-phosphate receptor 1 (S1PR1) ligand, ozanimod, on the regulation/activity of MMP-9 as well as endothelial barrier components (PECAM-1, claudin-5, and ZO-1) in human brain microvascular endothelial cells (HBMECs) following hypoxia plus glucose deprivation (HGD). We previously reported that S1PR1 activation improves HBMEC integrity; however, specific mechanisms underlying S1PR1 involvement in barrier integrity have not been clearly elucidated. We hypothesized that ozanimod would attenuate an HGD-induced increase in MMP-9 activity which would concomitantly attenuate the loss of integral barrier components. Male HBMECs were treated with ozanimod (0.5nM) or vehicle and exposed to 3h normoxia (21% O 2 ) or HGD (1% O 2 ). Immunoblotting, zymography, qRT-PCR, and immunocytochemical labeling techniques assessed processes related to MMP-9 and barrier markers. We observed that HGD acutely increased MMP-9 activity and reduced claudin-5 and PECAM-1 levels, and ozanimod attenuated these responses. In situ analysis via PROSPER, suggested that attenuation of MMP-9 activity may be a primary factor in maintaining these integral barrier proteins. We also observed that HGD increased intracellular mechanisms associated with augmented MMP-9 activation, however ozanimod had no effect on these targeted factors. Thus, we conclude that ozanimod has the potential to attenuate HGD mediated decreases in HBMEC integrity in part by decreasing MMP-9 activity as well as preserving barrier properties. Graphical

  • Ozanimod, an S1PR1 ligand, attenuates hypoxia plus glucose deprivation-induced autophagic flux and phenotypic switching in human brain VSM cells

    by Trevor S. Wendt, Yu Jing Li, Rayna J. Gonzales

    Vascular smooth muscle (VSM) cell phenotypic expression and autophagic state are dynamic responses to stress. Vascular pathologies, such as hypoxemia and ischemic injury, induce a synthetic VSM phenotype and autophagic flux resulting in a loss of vascular integrity and VSM cell death respectfully. Both clinical pilot and experimental stroke studies demonstrate that sphingosine-1-phosphate receptor (S1PR) modulation improves stroke outcome; however, specific mechanisms associated with a beneficial outcome at the level of the cerebrovasculature have not been clearly elucidated. We hypothesized that ozanimod, a selective S1PR type 1 ligand, will attenuate VSM synthetic phenotypic expression and autophagic flux in primary human brain VSM cells following acute hypoxia plus glucose deprivation (HGD; in vitro ischemic-like injury) exposure. Cells were treated with ozanimod and exposed to normoxia or HGD. Crystal violet staining, standard immunoblotting, and immunocytochemical labeling techniques assessed cellular morphology, vacuolization, phenotype, and autophagic state. We observed that HGD temporally decreased VSM cell viability and concomitantly increased vacuolization, both of which ozanimod reversed. HGD induced a simultaneous elevation and reduction in levels of pro- and antiautophagic proteins respectfully, and ozanimod attenuated this response. Protein levels of VSM phenotypic biomarkers, smoothelin and SM22, were decreased following HGD. Furthermore, we observed an HGD-induced epithelioid and synthetic morphological appearance accompanied by disorganized cytoskeletal filaments, which was rescued by ozanimod. Thus, we conclude that ozanimod, a selective S1PR1 ligand, protects against acute HGD-induced phenotypic switching and promotes cell survival, in part, by attenuating HGD-induced autophagic flux thus improving vascular patency in response to acute ischemia-like injury.